SteelPeak Wealth LLC Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

SteelPeak Wealth LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 147.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,860 shares of the biopharmaceutical company’s stock after acquiring an additional 4,090 shares during the quarter. SteelPeak Wealth LLC’s holdings in Alnylam Pharmaceuticals were worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Envestnet Portfolio Solutions Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $227,000. Envestnet Asset Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 30.4% in the third quarter. Envestnet Asset Management Inc. now owns 24,570 shares of the biopharmaceutical company’s stock worth $4,351,000 after acquiring an additional 5,727 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 52.4% in the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 311 shares in the last quarter. O Shaughnessy Asset Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 19.3% during the third quarter. O Shaughnessy Asset Management LLC now owns 1,594 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 258 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth about $1,952,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. BMO Capital Markets restated an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Royal Bank of Canada raised their target price on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 25th. SVB Leerink lifted their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research note on Tuesday, June 25th. Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 25th. Finally, William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Eight investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $247.09.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $243.00 on Monday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $252.87. The stock’s 50-day moving average is $159.86 and its two-hundred day moving average is $164.56. The stock has a market cap of $30.74 billion, a PE ratio of -90.67 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. The business’s quarterly revenue was up 54.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.40) earnings per share. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.92 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total value of $370,755.00. Following the completion of the transaction, the chief financial officer now directly owns 28,892 shares of the company’s stock, valued at approximately $6,674,052. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the sale, the executive vice president now directly owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jeffrey V. Poulton sold 1,605 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total transaction of $370,755.00. Following the transaction, the chief financial officer now owns 28,892 shares in the company, valued at $6,674,052. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,357 shares of company stock valued at $13,436,711. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.